Compare IQIYI Inc - ADR (IQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Merck & Co., Inc. — how do they compare? IQIYI Inc - ADR trades at $1.03 (market cap $974.67M), while Merck & Co., Inc. trades at $144.73 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 360.4× IQIYI Inc - ADR's market cap, and Merck & Co., Inc. pays a 2.39% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Merck & Co., Inc. for 98 Days on average.
| IQ | MRK | |
|---|---|---|
Market Cap | $974.67M | $351.28B |
Volume | 4,964,108 | 7,969,665 |
Sector | Media | Health |
52-Week High | $2.35 | $156.43 |
52-Week Low | $0.86 | $82.49 |
Typical Hold Time | 55 Days | 98 Days |
Enterprise Value | $2.47B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.015, up 0.5% with neutral technical signals. The company reported Q2 2026 revenue of $6.3 billion (up 1% sequentially) but posted a net loss of -$206 million in 2025. Valuation metrics show mixed signals with low P/S (0.25) and P/B (0.52) ratios but elevated P/E (144.05) due to negative earnings. Recent news highlights AI-driven content expansion with over 350 new titles announced for 2026-2027.
Investment outlook remains cautious despite analyst consensus leaning bullish (50% buy ratings). The streaming business faces revenue pressure with 2026 projections showing -3.22% net margin, though AI content initiatives could improve cost structure. Key risks include Chinese regulatory environment and streaming competition. Institutional sentiment appears divided given mixed technical indicators and fundamental challenges.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
